A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression free survival

Outcome Time Frame:

From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 36 months

Safety Issue:

No

Principal Investigator

Mary Mulcahy, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Northwestern University

Authority:

United States: Food and Drug Administration

Study ID:

TS-102

NCT ID:

NCT01483027

Start Date:

January 2012

Completion Date:

Related Keywords:

• Colorectal Cancer Metastatic
• Colorectal Neoplasms
• Neoplasms
• Neoplasms, Second Primary